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Background: The HIV-1 accessory proteins, Viral Infectivity Factor (Vif) and the pleiotropic Viral Protein R (Vpr) are
important for efficient virus replication. While in non-permissive cells an appropriate amount of Vif is critical to
counteract APOBEC3G-mediated host restriction, the Vpr-induced G2 arrest sets the stage for highest transcriptional
activity of the HIV-1 long terminal repeat.
Both vif and vpr mRNAs harbor their translational start codons within the intron bordering the non-coding leader
exons 2 and 3, respectively. Intron retention relies on functional cross-exon interactions between splice sites A1 and
D2 (for vif mRNA) and A2 and D3 (for vpr mRNA). More precisely, prior to the catalytic step of splicing, which would
lead to inclusion of the non-coding leader exons, binding of U1 snRNP to the 5' splice site (5'ss) facilitates recognition
of the 3'ss by U2 snRNP and also supports formation of vif and vpr mRNA.
Results: We identified a G run localized deep in the vpr AUG containing intron 3 (GI3-2), which was critical for balanced
splicing of both vif and vpr non-coding leader exons. Inactivation of GI3-2 resulted in excessive exon 3 splicing as
well as exon-definition mediated vpr mRNA formation. However, in an apparently mutually exclusive manner this
was incompatible with recognition of upstream exon 2 and vif mRNA processing. As a consequence, inactivation
of GI3-2 led to accumulation of Vpr protein with a concomitant reduction in Vif protein. We further demonstrate that
preventing hnRNP binding to intron 3 by GI3-2 mutation diminished levels of vif mRNA. In APOBEC3G-expressing but
not in APOBEC3G-deficient T cell lines, mutation of GI3-2 led to a considerable replication defect. Moreover, in HIV-1
isolates carrying an inactivating mutation in GI3-2, we identified an adjacent G-rich sequence (GI3-1), which was able to
substitute for the inactivated GI3-2.
Conclusions: The functionally conserved intronic G run in HIV-1 intron 3 plays a major role in the apparently mutually
exclusive exon selection of vif and vpr leader exons and hence in vif and vpr mRNA formation. The competition between
these exons determines the ability to evade APOBEC3G-mediated antiviral effects due to optimal vif expression.
Keywords: HIV-1 infection, Host restriction, Cytidine deaminase, APOBEC3G, Viral infectivity factor (Vif), Viral protein R (Vpr),
Alternative pre-mRNA splicing, G run, hnRNP F/H, Locked nucleic acids (LNAs)* Correspondence: schaal@uni-duesseldorf.de
1Institute for Virology, Medical Faculty, Heinrich-Heine-University Düsseldorf,
Universitätsstraße 1, Düsseldorf 40225, Germany
Full list of author information is available at the end of the article
© 2014 Widera et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Widera et al. Retrovirology 2014, 11:72 Page 2 of 19
http://www.retrovirology.com/content/11/1/72Background
The Human immunodeficiency virus type 1 (HIV-1)
exploits cellular components of the host cell for efficient
replication, while being counteracted by so called host
restriction factors, which have antiviral properties and
negatively affect viral replication.
Currently known host restriction factors consist of five
major classes that are the DNA deaminase subfamily
APOBEC3 (apolipoprotein B mRNA-editing enzyme,
catalytic polypeptide-like) [1-3], the Ubl conjugation
ligase TRIM5α (Tripartite motif-containing protein 5
alpha) [4-6], the integral membrane protein BST-2
(bone stromal tumor protein 2)/tetherin [7,8], the dNTP
hydrolase and RNase SAMHD1 (SAM domain and HD
domain-containing protein 1) [9-13], and the tRNA
binding protein SLFN11 (Schlafen 11) [14-16]. The
APOBEC3 (A3) family includes seven members (A3A to
A3D and A3F to A3H) that are located in a gene cluster
on chromosome 22 [17-19], from which A3D, A3F, A3G
and A3H have HIV-1 restrictive capacities [20-22]. They
are encapsidated in newly assembled virions, and fol-
lowing the subsequent infection of a host cell, introduce
C-to-U substitutions during minus-strand synthesis.
This results in G-to-A hypermutations in the HIV-1
genome, which negatively impact viral replication.
Hereby, A3G causes GG to AG transitions, whereas
A3D, A3F, and A3H lead to an overrepresentation of
GA to AA hypermutations [20,21,23-26]. However, the
HIV-1 encoded accessory protein Vif counteracts the
four A3 proteins by binding CBFβ and recruiting an E3
ubiquitin ligase complex, thus inducing their polyubi-
quitination and proteasomal degradation [20,27].
Since all early HIV-1 proteins are expressed from
spliced intronless viral mRNAs, splicing factors and spli-
cing regulatory proteins are particularly involved in viral
infection. Moreover, CAP-dependent translation is initi-
ated by binding of the 40S ribosomal subunit at the
mRNAs’ 5′end and by ribosomal scanning for an efficient
AUG. By using at least four 5′ splice sites (5′ss) and
eight 3′ splice sites (3′ss), the HIV-1 9 kb pre-mRNA is
processed into more than 40 alternatively spliced mRNA
isoforms [28] encoding at least 18 HIV-1 proteins, most
of them interacting with a wide variety of host cell com-
ponents [29]. Thus, HIV-1 relies on massive alternative
splicing to bring each of its eight translational start
codons (gag-pol, vif, vpr, tat, rev, nef, vpu, and env) into
close proximity of the 5′cap of the respective alternatively
spliced mRNA. The only exception to this rule is the env
ORF, which is translated from the bicistronic vpu/env
mRNA. Here, a minimal upstream ORF upstream of the
vpu ORF allows efficient translation initiation at the
downstream env AUG [30,31].
Within the 4 kb class of mRNAs (Figure 1A-B), down-
stream of 5′ss D2–D4 translational start codons arelocalized, which can only be recognized by the 40S ribo-
somal subunit if the respective introns are retained. In
particular, vif mRNA is formed when the intron upstream
of exon 2 is spliced out, while its downstream intron is
retained. In a similar way, vpr mRNA is formed by remov-
ing upstream introns carrying translational inhibitory
AUGs but repressing D3 and thus retaining intron 3.
Both mRNAs rely on functional cross-exon interactions
between the 5′ss and the corresponding upstream 3′ss
[32-34]. Thus, formation of unproductive spliceosomal
complexes at the 5′ss is essential for 3′ss activation and
exon definition as well as for splicing-repression at the
5′ss [35]. Hence, the expression levels of vif and vpr
mRNAs are dependent on U1 bound, but splicing repressed
5′ss [32,33].
Notably, excessive splicing at A2 was shown to result
in detrimental impairment of the balanced ratio of
spliced to unspliced viral mRNAs and loss of the viral
unspliced genomic 9 kb mRNA, a phenotype referred to
as oversplicing [36,37]. Since Gag and Pol are encoded
by the unspliced 9 kb mRNA, oversplicing decreases the
amounts of all Gag and Pol proteins including p55Gag
and p24-CA resulting in massive inhibition of viral particle
production and replication [36-39].
Moreover, transcripts containing either non-coding
leader exon 2 or 3 as required for vif and vpr mRNAs,
respectively, appear to be regulated in a similar way as
3′ss A1 and A2 recognition, which appears to underlie a
mutually exclusive selection [33]. However, the molecular
mechanism is still poorly understood.
Since 3′ss A2 was shown to be an intrinsically strong
3′ss [40], trans-acting elements are necessary to repress
its usage. Indeed, the ESSV within the non-coding leader
exon 3, which consists of three UAG motifs, has been
reported to inhibit splicing at 3′ss A2 [41-43]. In addition,
the Tra2-alpha and Tra2-beta-dependent splicing regula-
tory element ESEvpr positively regulates balanced amounts
of exon 3 recognition by acting positively on U1 snRNP
recruitment to 5′ss D3, which in turn promotes recognition
of the upstream 3′ss A2 via cross exon interaction [33].
Vpr formation was further proposed to be regulated by
high-mobility group A protein 1a (HMGA1a), which binds
immediately upstream of 5′ss D3 and acts to repress spli-
cing at this position. Here, trapping of U1 snRNP might
activate 3′ss A2 and repress splicing at 5′ss D3 [44].
Recently, we identified a G run with high affinity for
hnRNP F/H and A2/B1 proteins localized within intron
2 (GI2-1), but upstream of the vif AUG, which represses
usage of the alternative 5′ss D2b [34]. Mutations of GI2-1
led to considerable upregulation of vif mRNA expres-
sion [34]. Here, we analyzed whether regulation of exon
3 inclusion and processing of vpr mRNAs is regulated
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Figure 1 Schematic drawing of the HIV-1 NL4-3 genome. (A) The diagram illustrates the HIV-1 provirus genome including locations of open
reading frames (ORFs), long terminal repeats (LTRs), 5′ and 3′ splice sites (ss), exons, introns, and the Rev response element (RRE). Vif and vpr exons
and ORFs are highlighted in red and blue, respectively. The RRE is indicated by an open box. (B) Vif and vpr mRNA are formed primarily by splicing of
5′ss D1 to 3′ss A1 and A2, respectively. The noncoding leader exons 2 and 3 are included and AUG-containing introns are retained. (C) Sequence of
intron 3 in the proviral HIV-1 genome including the locations of the vpr AUG and G runs GI3-1 to GI3-4. The intrinsic strength of 5′ss D3 is indicated (HBS,
MAXENT). (D) Sequence logos generated from a sequence alignment of the HXB2 regions from nt 5581 - nt 5597 and nt 5708 - nt 5723, respectively,
flanking the four G runs GI3-1 to GI3-4. Sequences were obtained from the Los Alamos HIV Sequence Database (http://www.hiv.lanl.gov). The relative size
of the letters reflects the relative frequency of the nucleotides at the position in the alignment.
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The guanosine run element (GI3-2) localized deeply within
HIV-1 intron 3 is critical for efficient replication in PBMCs
Previously we have shown that an intronic G run within
HIV-1 intron 2 is critical for splicing regulation of vif
mRNA [34]. To examine whether an intronic G run is
likewise critical for regulation of vpr mRNA, whose
processing similarly depends on intron retention, we
inspected HIV-1 intron 3 for the occurrence of G runs.
Since they are highly abundant in mammalian introns
[45-47], it was not surprising that we found four G runs,
which we termed GI3-1 to GI3-4 according to their 5′ to
3′ localization (Figure 1). However, only two of these,
GI3-2 and GI3-3, were found to match the consensus
motif DGGGD (where D is G, A, or T) of the high affinity
binding site for members of the hnRNP F/H family [48].
Moreover, since GI3-2 and GI3-3 were highly conserved
in HIV-1 strains (Figure 1D), we analyzed whether one
or even both had an impact on viral replication. To this
end, we disrupted each of them in the molecular clone
pNL4-3 by introducing single nucleotide substitutions
(pNL4-3 GI3-2 mut: AGGGA > AGAGA, pNL4-3 GI3-3
mut: GGGGA > GGCGA). Since for GI3-2 it was not
possible to introduce a mutation without changing the
coding sequence of the overlapping vif and vpr open
reading frames (ORFs), we chose a nucleotide substitu-
tion, which was present in HIV-1 subtypes J, G, and AE
(Figure 2A, C). This exchange, however, resulted in a
single amino acid substitution within the C terminus of
Vif (AGGGA > AGAGA, G185E). To be able to infect
PBMCs with equal amounts of viral particles, we first
transfected HEK 293 T cells with the proviral plasmid
pNL4-3 or its mutant derivates, pNL4-3 GI3-2 mut or
pNL4-3 GI3-3 mut, and then harvested virus-containing
supernatants 48 h post transfection. The TCID50 were
calculated by X-Gal staining of infected TZM-bl reporter
cells. These cells carry a luciferase and β-galactosidase
expression cassette under the control of the HIV-1 LTR
and thus express both reporter genes in the presence of
HIV-1 Tat [49]. With a multiplicity of infection (MOI) of
each of 0.05 and 0.5, PBMCs from two healthy donors
were then infected and p24-CA protein levels were deter-
mined at various time points. As shown in Figure 3, GI3-3,
but not GI3-2 mutated virus, was able to replicate in
PBMCs indicating that specifically GI3-2 was critical for
efficient virus replication in primary T cells.
Mutating GI3-2 results in an impaired ratio of spliced to
unspliced mRNAs
In order to investigate the molecular cause for the replica-
tion defect of GI3-2 mutant virus, we analyzed the splicing
patterns of proviral DNA from pNL4-3 and G run mutant.
To this end, total RNA of HEK 293 T cells transfected
with each of the proviral DNAs was subjected to Northernblot analysis and probed with a DIG-labeled HIV-1 exon 7
amplicon detecting all viral mRNA classes. While the
overall splicing pattern was not changed for the GI3-3 pro-
virus (data not shown), inactivation of GI3-2 caused
massive disturbance of the balanced ratio of the three
viral mRNA classes with the most obvious decrease in
the amount of unspliced 9 kb mRNA (Figure 4A-B).
Concomitantly, the ratio of 2 and 4 kb mRNA classes was
increased indicating massive splicing defects (Figure 4B).
In order to quantify the amounts of the viral RNA
classes, we performed quantitative RT-PCR analysis using
primers (Additional file 1: Figure S1) binding in intron 1
(gag-pol) to detect unspliced 9 kb mRNA, as well as
primers to quantify the relative amount of multiply spliced
mRNAs (exon junction D4/A7). As shown in Figure 4C,
the relative amount of unspliced, i.e. intron 1 containing
mRNAs, was three-fold decreased compared to the amount
from non-mutated virus. In parallel, the relative amount
of multiply spliced mRNAs was three-fold increased.
Thus, inactivation of GI3-2 shifted the balance towards
intronless viral mRNAs.
Since p24-CA protein is encoded by the unspliced 9 kb
mRNA, the widening gap between unspliced and multiply
spliced mRNAs that has been previously described and
referred to as oversplicing or excessive splicing [36-39]
might result in diminished viral p24-CA production. How-
ever, since unspliced 9 kb mRNA was still detectable in
the Northern blot analysis of GI3-2 mutant virus, a lower
level of viral particle production was probably not the only
cause of the totally abolished replication of GI3-2 mutant
virus in PBMCs.
GI3-2 plays a major role in exon 2 vs. exon 3 selection
and vif vs. vpr mRNA expression
Since activated PBMCs exhibit high expression of the
host restriction factor A3G [34,50], we were interested
in whether the replication defect of GI3-2 mutant virus
might have originated from disturbed expression of the
viral antagonist of A3G, which is the accessory protein
Vif. For this purpose, we analyzed the impact of the GI3-
2 inactivating mutation on vif gene expression. HEK
293 T cells were transiently transfected with pNL4-3 or
the GI3-2 mutant proviral plasmid pNL4-3 GI3-2 mut,
and total RNA and proteins were harvested 48 h post
transfection. As determined by semi-quantitative RT-PCR
using primer pairs to specifically amplify intron-containing
(4 kb) or intronless (2 kb) HIV-1 mRNAs (Additional file 1:
Figure S1), inactivation of GI3-2 resulted in excessive
exon 3 splicing in the tat, nef, and env mRNAs (Tat3,
Nef4, Env8), and concomitantly led to accumulation of
vpr mRNA indicating that GI3-2 represses exon 3 and 3′ss
A2 recognition (Figure 5A). However, enhanced splicing
of A2 was obviously incompatible with the recognition of
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Figure 2 Comparison of intron 3 G runs and their sequence surroundings in HIV-1 subtypes. (A-B) Proviral DNA sequence surroundings of
the HIV-1 consensus sequences A1 to AE of GI3-1 to GI3-4. Conserved sequences are represented by –, deviants by letters. Conserved G run motifs
are highlighted by grey boxes. The ORF of vif and vpr including start and stop codons are indicated as declining boxes. The subtype sequences
were analyzed with the RIP 3.0 software (http://www.hiv.lanl.gov/content/sequence/RIP/RIP.html). (C) Molecular clones of pNL4-3 used in this study.
Sequences of G runs GI3-1 and GI3-2 including surrounding nucleotides are depicted. Mutated sequences are represented by letters. Corresponding
consensus sequences are indicated on the right. (D) The amino acid substitutions of the proviral clones used in this study. The sequence of G runs
GI3-1 and GI3-2 including surrounding nucleotides is depicted. Substituted amino acids and their position in Vif Protein are shown in the table.
Corresponding consensus sequences are indicated on the right.
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processing (Figure 5A). Mutating GI3-2 considerably
shifted from exon 2 to exon 3 containing transcripts indi-
cating that GI3-2 balances selection of exon 2 and exon 3.
To quantify the impact of inactivated GI3-2 on balanced
regulation of exon 2 and 3 splicing, we performed quanti-
tative real time RT-PCR using primer pairs (c.f. Additional
file 1: Figure S1 for primer binding sites) detecting the
relative splicing efficiencies of mRNAs containing either
exon 2 or 3 as well as the relative splicing efficiencies of
vpr and vif mRNAs (Figure 5B and C). We quantified a
44-fold increase in exon 3 and concomitant three-fold
decrease in exon 2 containing transcripts (Figure 5B).
Furthermore, we quantified a 30-fold increase of vpr
mRNA, when GI3-2 was mutated confirming that GI3-2 is
also required for the repression of 3′ss A2 (Figure 5C).
On the other hand, vif mRNA was observed to decrease
2.5-fold compared to the non-mutated virus, verifying
the aforementioned observation that 3′ss A1 and A2 arespliced in an apparently mutually exclusive manner
(Figure 5C). This was furthermore confirmed by the
quantitation of the relative splicing efficiency of tat
mRNAs of GI3-2 mutant virus, which resulted in consider-
able increase in tat3 (18-fold) and concomitant decrease
of tat2 (four-fold) mRNA splicing (Figure 5D).
Next, we performed Western blot analyses to evaluate
excessive exon 3 splicing and opposite effects on vpr and
vif mRNA splicing also on protein levels (Figure 5E and F).
In accordance with decreased amounts of unspliced
mRNAs, we observed a remarkable decrease in Gag
expression, which was mainly reflected by the reduced
amounts of its cleavage products. Similarly, virus particles
in the supernatant were decreased (Figure 5E, p24-CA
(sn)). As expected from the RT-PCR results described
above, the expression of Vpr protein was considerably
increased when GI3-2 was mutated. In parallel, Vif protein
amounts were significantly decreased to 65% when











































Figure 3 G run GI3-2 is crucial for efficient virus replication in
PBMCs. Peripheral blood mononuclear cells from two healthy donors
were infected with NL4-3 virus or mutant derivatives with the indicated
multiplicity of infection (MOI). Virus production was determined by










































Figure 4 GI3-2 causes alterations in mRNA processing. (A) Northern blo
wild type or mutant pNL4-3 was isolated 48 h post transfection. RNA was s
on a positively charged nylon membrane and UV cross-linked. The membr
(B) Quantitation of relative amounts of mRNAs from (A). (C) RNA from pan
specific for intron 1 containing mRNAs of the 9 kb mRNA class (#3389/#339
normalized to exon 7 containing mRNAs (#3387/#3388).
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tivation of 3′ss A2 and plays a major role in the apparently
mutually exclusive selection of exon 2 and exon 3, which in
turn regulates the expression of Vpr and Vif protein.GI3-2 is critical for viral replication in APOBEC3G-
expressing but not -deficient cells
Since physiological levels of Vif are necessary to counteract
A3G-mediated host restriction, we were interested in
whether the diminished Vif protein levels of GI3-2 mutated
virus were the underlying cause of the replication in-
competence in PBMCs. In order to prove this hypoth-
esis, we aimed to analyze the replication kinetics of
mutant and non-mutant virus in A3G low expressing
CEM-SS [2,51-53] and high expressing CEM-A [54] cell
lines, whose expression we previously confirmed by A3G
immunoblot analysis [34]. As a control, the vif deficient
NL4-3 Δvif virus was included in this analysis [55]. CEM
cells were infected with an MOI of 0.01, cell free superna-
tants were harvested at frequent intervals, and p24 capsid
protein production (CA) was monitored by capture
ELISA to quantify viral replication (Figure 6A). As an-
ticipated, in A3G low expressing CEM-SS cells, vif defi-
cient virus was able to produce viral particles with
comparable efficiency as non-mutant NL4-3 virus. How-
ever, the replication curve of GI3-2 mutant virus flattened
out at a tenfold lower p24-CA amount compared to non-
mutant and vif deficient virus, confirming that inactivating
GI3-2 not exclusively alters vif mRNA processing but
generally disturbs the balanced ratio of all classes of RNA
impairing viral replication. On the contrary, vif deficient
as well as GI3-2 inactivated viruses were replication
incompetent in A3G high expressing CEM-A cells and
thus ended up in an abortive infection. These results
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vpr mRNA vif mRNA
Figure 5 Mutation GI3-2 increases vpr, but decreases vif mRNA and Vif protein levels. (A) RT-PCR analysis of RNA from HEK 293 T cells
transiently transfected with pNL4-3 or its GI3-2 mutant derivate. Compare with Additional file 1: Figure S1 for specific primer binding sites. RNA
was isolated 48 h post transfection. Primer pairs are indicated at the bottom of each panel, transcript isoforms on the right. To compare total
RNA amounts, separate RT-PCRs were performed by using primer pairs amplifying HIV-1 exon 7 and cellular GAPDH sequence. PCR amplicons
were separated on a non-denaturing polyacrylamide gel (10%) and stained with ethidium bromide. (B-D) Quantitative RT-PCR of total RNA from
(A) using primers indicated in Additional file 1: Figure S1. The NL4-3 splicing pattern (wt) was set to 100% and the relative splice site usage was
normalized to exon 7 containing HIV-1 transcripts. (E) Immunoblot analysis of the indicated proteins employing lysates or pelleted virions from
supernatant (sn) obtained from HEK 293 T cells that were transiently transfected with wild type or GI3-2 mutant proviral DNA. Transfected cells
were lysed in RIPA buffer and the lysates were collected 48 h post transfection. Cell-free supernatant was concentrated by sucrose centrifugation.
(F) Quantification of Vif protein amounts from (E).
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virus production caused by the G run mutation. These
results also demonstrate that GI3-2 was critical for effi-
cient virus replication in A3G expressing cells and thatthe threshold of Vif required for optimal viral replication
was in a narrow range.
To determine the viral rescuing activity of Vif and Vif
























































































































































































Figure 6 GI3-2 is critical for efficient virus replication in A3G expressing cells. (A) CEM-SS and CEM-A cells were infected with wild type or
GI3-2 mutant NL4-3 virus and virus production was determined by p24 CA capture ELISA of cell-free supernatant collected at the indicated time points.
(B) Vif G185E mutant counteracts A3G with comparable efficiency as wild type Vif. Viral rescuing activity of Vif and Vif G185E mutant against A3G compared
to vector only control (no A3G). HIV-1 Δvif.luc reporter viruses were generated in the presence of A3G and absence of A3G (vector control), and A3G in
combination with Vif, Vif G185E, Vif-V5, and Vif-V5 G185E plasmids. Virions were normalized by RT activity. Luciferase activity was measured 48 hours post
infection. Unpaired t tests were computed to determine the differences between the group of samples reached the level of statistical significance (ns, not
significant; *, P 0.05 and ***, P 0.0001). (C) Viral supernatants were concentrated through a 20% sucrose cushion by ultracentrifugation. Immunoblot analysis
of the expression and encapsidation of A3G in the presence and absence of Vif, Vif G185E, Vif-V5, and Vif-V5 G185E: A3G was detected by an anti (α)-HA
antibody. Vif, VSV-G, and p24-CA were detected by their respective monoclonal antibodies. Tubulin served as loading control for cell lysates and p24-CA
and VSV-G for viral lysates. Asterisk in the Vif blot indicates the shift in the molecular weight of V5-tagged Vif.
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tag. The point mutation yielding to the amino acid sub-
stitution G185E was introduced in both plasmids by site
directed mutagenesis and used to produce viral particles
by transfection of HEK 293 T cells. Normalized amounts
of particles were used to transduce HEK 293 T cells and
the intracellular luciferase activity was quantified two
days post transduction. A3G reduced the infectivity of
HIV-1 luc reporter vectors about 10-fold, and the pres-
ence of Vif and Vif G185E (both versions) rescued the
reporter virus infectivity to above 70% attained by HIV-1
vectors generated without A3G (Figure 6B). Immunoblot
analysis of cellular and viral lysates confirmed wild type
Vif- and G185E mutant Vif-triggered proteosomal deg-
radation of A3G in the viral producer cells (Figure 6C).
In the absence of Vif or Vif G185E, A3G was efficiently
incorporated in the viral particles. However, in the presence
of Vif or Vif G185E only traces of A3G were detectable in
encapsidated viruses. The amount of Vif and Vif G185E
within the viral particles was under the detection limit.
In conclusion, GI3-2 is critical for efficient virus repli-
cation in A3G expressing cells while G185E mutation
does not alter the Vif protein’s counteracting function.
Inhibition of hnRNP protein binding to the intronic G run
GI3-2 restricts viral particle production
Since G runs were demonstrated to act as high affinity
binding sites for members of the hnRNP F/H and A2/B1
protein families [34,48], RNA affinity precipitation assays
were performed to screen for potential interaction also
with the viral G run GI3-2. Therefore, short RNA oligo-
nucleotides containing an MS2 coat protein RNA stem
loop (Figure 7A), and either the wild type or mutant
GI3-2 sequence, were transcribed in vitro. The RNAs
were then covalently immobilized on agarose beads and
incubated in HeLa cell nuclear extract supplemented with
recombinant MS2 coat protein to allow monitoring RNA
pull-down efficiency. Subsequently, the associated pro-
teins were eluted and separated on SDS-PAGE and sub-
jected to immunoblot analysis (Figure 7B). As expected,
we could detect high levels of hnRNP F/H and A2/B1
proteins on RNAs containing the wild type GI3-2
sequence, while these were markedly reduced for the
mutated RNA substrate (Figure 7B, upper and middle
panel, lanes 3 and 4). Noticeably, equal levels of MS2 pro-
tein detected on wild type and mutated RNAs indicated
comparable precipitation efficiencies for both RNAs
(Figure 7B, lower panel, lanes 3 and 4) and therefore sug-
gested that hnRNP F/H and/or A2/B1 may act through the
GI3-2 sequence to contribute to splicing regulation of vif
and vpr mRNAs.
To test whether hnRNP binding can be prevented by
masking GI3-2 sequence using an RNA-based antisense
approach, we also determined the precipitated levels ofhnRNP F/H and A2/B1 proteins together with wild type
RNAs in presence of a locked nucleic acid (LNA) specif-
ically targeting the GI3-2 sequence (GI3-2 LNA). Herein,
decreased levels of hnRNP F/H and A2/B1 proteins were
detected on wild type RNA to which the GI3-2 LNA had
been added (Figure 7B, cf. lanes 3 and 5). Moreover, upon
increasing the concentration of the GI3-2 LNA, hnRNP F/
H and A2/B1 precipitation efficiency could be further
slightly reduced (Figure 7B, cf. lanes 3, 5 and 6). Altogether,
these results demonstrate that this LNA rendered GI3-2
inaccessible for hnRNP F/H and A2/B1 binding.
Next, we were interested in whether the GI3-2 LNA
might be suitable to impair viral particle production.
Following co-transfection of HeLa cells with pNL4-3 and
either the GI3-2 LNA or a control LNA (GI3-2 MM LNA)
that contained three mismatches, total RNA was harvested
and analyzed by Northern blotting using a HIV-1 exon 7
specific probe. Co-transfection of the GI3-2 LNA resulted
in a considerable reduction in viral RNAs compared to
pNL4-3 alone or pNL4-3 co-transfected with the mismatch
control LNA, GI3-2 MM (Figure 7C). To further determine
whether viral particle production and Gag protein expres-
sion were also affected, total proteins of the transfected cells
and the virus containing supernatant were subjected to
immunoblot analysis and detected with a p24-CA specific
antibody. In line with the above findings, Gag precursor
(Pr55gag) as well as Gag processing intermediate (Pr41)
and product (p24-CA) were significantly reduced in the
presence of the GI3-2 LNA (Figure 7D). There was little
effect on the Gag protein expression and virus production
when co-transfecting the GI3-2 MM LNA emphasizing
the specificity of the GI3-2 LNA and the impact of GI3-2
on viral particle production.
The GI3-2 binding site is functionally conserved in HIV-1
To assess whether GI3-2 might be a valuable target for
LNA-mediated antiviral therapy, we were interested in
whether GI3-2 is conserved in all HIV-1 subtypes. Indeed,
an alignment of all HIV-1 consensus sequences showed
that 9 out of 12 consensus sequences encode a conserved
G run at the designated position (Figure 2A). The re-
maining three subtypes lacking a G run at this particular
position contain a G run only 6 nucleotides upstream due
to a compensatory nucleotide substitution in position 2 of
GI3-1 restoring the protein binding consensus sequence
DGGGD. The A >G substitution in GI3-1 likely converts a
low affinity (AAGGGC) into a high affinity binding site
(AGGGGC). To demonstrate that the compensatory GI3-
1 mutation could functionally substitute for an inactivated
downstream GI3-2 binding site we inserted the corre-
sponding mutations into pNL4-3 and pNL4-3 GI3-2 mut
(Figure 2C) and determined their splicing outcomes. Total
RNA was isolated 24 h following transient transfection
































































5´- CAAGGGCCACAGAGGGAGCCAUACAAUGAA - 3´
5´- --------------A--------------- - 3´
3´- GUGUCUCCCUCGGUAU - 5´
3´- GUGcCUCaCUCGGUaU - 5´
Figure 7 GI3-2 is specifically bound by hnRNP F/H and A2/B1. (A) Schematic illustration of the RNA pull-down experiment and binding site
of locked nucleic acids directed against GI3-2 within HIV-1 intron 3. (B) RNA pull-down assay using HeLa nuclear extract. Substrate RNAs containing a
MS2 sequence and the wild type or mutant G runs sequence were covalently linked to adipic acid dihydrazide-agarose beads and incubated with
HeLa cell nuclear protein extract. MS2-proteins were added to monitor the RNA input. For interference with protein:RNA interaction, wt RNA was
pre-incubated with the GI3-2 LNA in a ratio of either 1:5 or 1:1 relative to the amount of RNA substrate. The precipitated proteins were resolved by
SDS-PAGE (16%) and detected by immunoblot analysis using anti hnRNP F/H and A2/B1 antibodies. MS2 specific antibodies were used as a loading
control. (C) HeLa cells were co-transfected with pNL4-3 and locked nucleic acids (LNAs) masking GI3-2 or the respective mismatch control. Total RNA
was isolated 24 h post transfection and subjected to Northern blotting using a HIV-1 specific probe. (D) Immunoblot analysis of p24-CA using cellular
lysates (cell) and pelleted virions from the supernatant (sn) of co-transfected cells from (C).
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(Figure 8B). Introducing an A >G mutation in position 2
of GI3-1 while GI3-2 was inactivated by the G > A muta-
tion, we could compensate the excessive exon 3 and vpr
mRNA splicing phenotype described above and restored
the amounts of exon 2 containing transcripts (Figure 8A,
lane 3) as well as vif mRNA (Figure 8B). These resultsdemonstrate that the A >G nucleotide change in position
2 of GI3-1 (cf. Figure 2C; J, G, AE) is a compensatory
mutation. The introduction of this substitution without
inactivating downstream GI3-2 had no effect on vif and
vpr mRNA amounts (Figure 8A-B, cf. lanes 1 and 5)
suggesting that there is no evolutionary pressure on two






























































































































































































































Figure 8 A single G run is sufficient to maintain the HIV-1 splicing pattern. (A) RT-PCR analysis of RNA isolated from HEK 293 T cells transiently
transfected with pNL4-3 or its mutant derivates 48 h post transfection. The used primer pairs are illustrated in Additional file 1: Figure S1. Transcript
isoforms are indicated on the right. Separate RT-PCRs were performed by using primer pairs amplifying HIV-1 exon 7 to compare total RNA amounts.
PCR amplicons were separated on a non-denaturing polyacrylamide gel (10%) and stained with ethidium bromide. (B-C) Quantitative RT-PCR of total
RNA obtained from panel (A). The NL4-3 splicing pattern (wt) was set to 100% and the relative splice site usage was normalized to exon 7 containing
HIV-1 transcripts. Compare with Additional file 1: Figure S1 for specific primer binding sites. (D) Immunoblot analysis of the indicated proteins employing
lysates from HEK 293 T cells (cellular) and their supernatants (sn) transiently transfected with the indicated proviral DNAs. Transfected cells were lysed in
RIPA buffer and lysates were collected 48 h post transfection. Virions were pelleted by sucrose centrifugation.
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rescuing Vif and Vpr protein levels, we isolated total
cellular proteins and subjected them to immunoblot
analysis. Consistent with the findings above, the com-
pensatory A > G mutation reduced Vpr amounts and
restored Vif protein levels to those levels obtained with
wild type pNL4-3 (Figure 8D, Vpr, Vif ). In addition, the
reduced amount in Gag precursor as well as viral particle
production could be rescued (Figure 8D, p24-CA). The
data obtained in these experiments highlights a functional
conservation of the G run in all HIV-1 subtypes support-
ing an indispensable role for GI3-2 in HIV-1 replication.
Discussion
Within HIV-1 NL4-3 intron 3 we identified a high affin-
ity binding site for members of the hnRNP F/H family,
termed GI3-2. Binding of hnRNP F/H and A2/B1 proteins
to GI3-2 was confirmed by RNA pull-down experiments
and could be efficiently prevented either by point muta-
tion or upon co-transfection with an LNA specifically
targeting GI3-2. Inactivation of GI3-2 led to aberrant alter-
native splicing and to a replication defective phenotype in
PBMCs and A3G expressing CEM-A cells.
The GI3-2 inactivating mutation resulted at the same
time in an amino acid (aa) substitution at position 185
(G185E) in the Vif protein, which is localized in the Gag,
p7-NC, and membrane binding domain [27]. Residues
172 to 192 were shown to be involved in membrane
association [56], and mutating aa positions 179 to 184
(KTKGHR > ATAGHA) resulted in 25% loss of membrane
binding and decreased Pr55Gag binding [57]. However, a
T > A substitution at aa position 188 of Vif had no effect
on the ability to decrease A3G levels [58]. Moreover, since
the G185E substitution in Vif is also present in three
(G, J and AE) of twelve HIV-1 consensus sequences, we
assumed that it is highly unlikely that it affects Vif ’s
A3G counteracting activity. However, to experimentally
rule out that the Vif G185E substitution indeed did not
impact Vif ’s functionality we confirmed it by using an
HIV-1 Vif deficient luciferase reporter, which was
supplemented with expression vectors coding for either
wild type or G185E Vif protein.
At the RNA level, in parallel to an increase in exon 3
recognition, mutating GI3-2 also decreased levels of exon
2 containing transcripts as well as vif mRNA, demonstrat-
ing that recognition of either exon strongly influences
the other. Indeed, we have shown recently that excessive
splicing of exon 3 and vpr mRNA processing concomi-
tantly resulted in considerable decrease of exon 2 and
vif mRNA splicing, indicating an apparently mutually
exclusive exon selection of exon 2 and exon 3 [33]. In
this work we demonstrated that this competition, which
is regulated by GI3-2, determines the ability to evade
A3G-mediated antiviral effects due to vif expression.Hence, an insufficient level of Vif is unable to maintain
viral replication due to insufficient A3G-counteraction.
All HIV-1 intron-containing mRNAs that harbor
translational start codons in their introns immediately
downstream of their leader exon (avoiding translational
inhibitory AUGs) depend on the recognition of the leader
exons’ 3′ss. However, their corresponding 5′ss must be
rendered splicing incompetent in order to include the
start codons into the nascent transcript. For instance, the
intron-containing env mRNAs, which belong to the class
of HIV-1 4 kb mRNAs, are formed by using a splice
acceptor that is derived from either one of the 3′ss central
cluster (A4c, a, b and A5), and splicing repression at D4.
Hereby, U1 bound to D4 and U2 snRNPs bound to 3′ss
A4cab or A5 pair with each other via cross-exon inter-
actions [35] and facilitate exon definition [59,60]. In
addition, these interactions are supported by the strong
guanosine-adenosine-rich enhancer GAR ESE, which is
localized immediately downstream of 3′ss A5 [35,61].
Importantly, the binding of a splicing incompetent U1
snRNA was sufficient to promote exon definition and 3′
ss activation indicating that exon definition but not spli-
cing at D4 is crucial to activate upstream splice acceptor
usage in order to gain env/vpu mRNAs [35]. In a similar
way, vif and vpr mRNAs seem to rely on comparable
functional cross-exon interactions, in these cases between
splice sites A1 and D2 (exon 2) as well as A2 and D3
(exon 3), respectively, which determined the splicing
efficiency of vif and vpr mRNA. In agreement with the
formation of env/vpu mRNAs, exon 3 inclusion and vpr
mRNA expression can be modulated by up and down
mutations of 5′ss D3 as well as by co-transfection of
modified U1 snRNAs with perfect complementarity to
the 5′ss D3 [33,37]. Hereby, binding of U1 snRNP to a
non-functional 5′ss was shown to be already sufficient
to enhance splicing at the upstream 3′ss A2 indicating
that vpr encoding mRNAs are dependent on the relative
occurrence of U1-bound, but splicing-repressed 5′ss [33].
Correspondingly, the co-expression of a U1 snRNA that
was fully complementary to a splicing deficient HIV-1 D2
mutant was sufficient to maintain vif mRNA formation
[32]. Since both D3 up [33] as well as GI3-2 mutations
increased exon 3 inclusion as well as vpr formation, it
seems plausible that GI3-2 might play a role in the inhib-
ition of U1 snRNP recruitment to D3.
So far vif mRNA formation has been known to be
maintained by the two SRSF1 dependent heptameric
exonic splicing enhancers ESEM1 and ESEM2 [40], the
SRSF4 dependent ESE Vif [32], as well by the intronic G
rich silencer elements G4 overlapping with the intronic
nucleotides of 5′ss D2 and thus likely competing with
U1 snRNP binding [32]. In addition, we recently identi-
fied the intronic G run GI2-1, which impairs usage of the
HIV-1 alternative 5′ss D2b as well as exon definition of
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we show that vif mRNA is not only regulated by exon 2
and exon 2b associated SREs [32,34,40], but in addition
is also controlled by the balanced exon recognition and
splicing of exon 2 and exon 3. In contrast to GI2-1,
GI3-2 is entitled as a “deep intronic” splicing regulatory
element. The mechanism, although not yet known,
seems likely to be different to that described for GI2-1.
Whereas any splicing regulatory element immediately
upstream or downstream of a 5′ss exerts a clear pos-
itional splicing regulatory effect [62] this is unpredictable
for deeper intronic ones. Thus, the intronic G runs, GI3-
1 and GI3-2, extend the repertoire of SREs, acting on vif
and vpr mRNA splicing regulation.
Conserved non-coding sequences often harbor cis-
regulatory elements that can vary in their sequence.
However, since GI3-1 and GI3-2 are localized in both vif
and vpr ORFs, there is little room left to maintain
proper protein affinity forming a compromise between
splicing efficiency on the one hand and protein function on
the other hand. Comparing HIV-1 consensus sequences
(Los Alamos HIV database) it turned out that GI3-2
matches the consensus sequences of HIV-1 strains A2, B
and D. In addition, the three consensus sequences of
strains J, G and AE were equivalent to the inactivating
GI3-2 mutation but contained a high affinity hnRNP F/H
binding site in position of GI3-1 (comparable to GI3-1 cmp/
GI3-2 mut). However, most of the consensus sequences
contain both G runs, GI3-1 and GI3-2, as high affinity bind-
ing sites. Thus, removal of only a single G run preserves
phenotypic functioning indicating that a single protein
binding site irrespective of the exact nucleotide sequence is
sufficient to maintain proper splicing. Since viral replication
of GI3-2 mutant NL4-3 virus was considerably impaired in
A3G-expressing, but not in -deficient cells, we propose that
at least one functional high affinity binding site for hnRNP
F/H and A2/B1, either GI3-1 or GI3-2, is critical to maintain
an optimal Vif to A3G ratio. Further support for this model
comes from previous studies showing that siRNA-directed
down-regulation of hnRNP A2/B1 proteins within pNL4-3-
transfected HEK 293 T cells leads to a viral oversplicing
phenotype of exon 3 containing and vpr coding mRNAs
reminiscent to that seen for the GI3-2 mutant [63,64]. In
addition, the redundancy of these G runs could represent
a viral backup mechanism to easily re-substitute defect
binding sites by an exchange of a single nucleotide.
Targeting Vif gene expression represents an attractive
therapeutic strategy as it supports infected cells to defend
themselves in an APOBEC3-dependent manner. Since
viral replication of GI3-2 mutant NL4-3 virus was strongly
impaired in human primary T-lymphocytes, G runs GI3-1
and GI3-2 may represent suitable therapeutic targets.
Therefore we tested the effect of an LNA specifically
designed to target GI3-2 on viral particle production.Surprisingly, we found that targeting GI3-2 had an even
more dramatic effect on the viral particle production than
inactivating GI3-2 upon mutation. This apparent stronger
effect might to some extend result from an yet unknown
degradation mechanism of the viral target RNAs. Since we
used mixmer LNAs (combination of LNA and DNA resi-
dues) it is highly unlikely that they recruit RNaseH, which
has been shown to need at least a gap of 6 neighbouring
deoxynucleotides for noteworthy RNase H activity [65,66].
Although the mechanism of action is not yet fully under-
stood, viral particle production seems to be specific as the
control mismatch LNA did not cause any harm.
Since sublethal levels are proposed to contribute to
viral genetic diversity, suboptimal Vif inactivation might
give rise to the emergence of viral quasi-species and
drug resistant HIV-1 strains [1,67,68]. Hence, there is a
need for multiple therapeutic approaches to inactivate
Vif in parallel. Potentially, this can be achieved by masking
numerous SREs that facilitate vif expression. Furthermore,
this strategy could minimize the risk of second site
mutations that may potentially substitute therapeutically
induced aberrant splicing. Moreover, it will be interesting
to analyze the effect of GI3-2-mutation derived increase of
Vpr protein levels, which are important for HIV-1 replica-
tion in macrophages.
Conclusions
Our data suggest that the intronic G runs GI3-1 and GI3-2,
which are functionally conserved in most HIV-1 strains,
are critical for efficient viral replication in A3G-expressing
but not in A3G-deficient T cell lines. Hereby, inactivation
of GI3-2 results in increased levels of both mRNA and
protein levels of Vpr, but concomitantly in decreased
amounts of Vif mRNA and protein levels. GI3-2, which is
bound by hnRNP F/H and A2/B1 proteins, plays a major
role in the apparent mutually exclusive exon selection of
vif and vpr leader exon selection. Furthermore, mutating
GI3-2 decreased viral mRNA levels, altered the ratio of
unspliced 9 kb mRNA and thus reduced viral production.
Since competition between these exons determines the
ability to evade A3G-mediated antiviral effects due to
vif expression, we propose that GI3-2 is critical for viral
replication in non-permissive cells due to an optimal




Proviral DNA pNL4-3 GI3-2 mut was generated by
replacing the AflII/NarI fragment of pNL4-3 [GenBank:
M19921] [69] by the PCR-amplicon obtained by using
primer pair #2339/#3896 (for all sequences see Table 1).
Proviral plasmid pNL4-3 GI3-3 mut was generated by
substitution of the EcoRI/NdeI fragment of pNL4-3 with
Table 1 DNA oligonucleotides used in this work
Primer Primer sequence
#0640 5′- CAATACTACT TCTTGTGGGT TGG
#1544 5′- CTTGAAAGCG AAAGTAAAGC
#2330 5′- TCTGGATCCA CCACCACCAC CGTAGAT
#2339 5′- TGGGAGCTCT CTGGCTAACT AGG
GAACCCACTGCTTAAGC
#3153 5′- CCACTCCTCC ACCTTTGAC
#3154 5′- ACCCTGTTGC TGTAGCCA
#3387 5′- TTGCTCAATG CCACAGCCAT
#3388 5′- TTTGACCACT TGCCACCCAT
#3389 5′- TTCTTCAGAG CAGACCAGAG C
#3390 5′- GCTGCCAAAG AGTGATCTGA
#3391 5′- TCTATCAAAG CAACCCACCTC
#3392 5′- CGTCCCAGAT AAGTGCTAAGG
#3395 5′- GGCGACTGGG ACAGCA
#3396 5′- CCTGTCTACT TGCCACAC
#3397 5′- CGGCGACTGA ATCTGCTAT
#3398 5′- CCTAACACTA GGCAAAGGTG
#3631 5′- CGGCGACTGA ATTGGGTGT
#3632 5′- TGGATGCTTC CAGGGCTC
#3633 5′- CGACACCCAA TTCTTGTTAT GTC
#3636 5′- CCGCTTCTTC CTTGTTATGT C
#3896 5′- TTCACTCTTA AGTTCCTCTA AAAGCTCTAG
TGTCCATTCA TTGTATGGCT CTCTCTGTGG C
CCTTGGTCT TCTG
#3897 5′- GTTGCAGAAT TCTTATTATG GCTTCCACTC
CTGCCCAAGT ATCGCCGTAA GTTTCATAGA T
ATGTTGTCC TAAGTTATG
#4324 5′- TAATACGACT CACTATAGG
#4355 5′- TTCATCGAAT TCAGTGCCAA GAAGAAAAGC
AAAGATCA
#4614 5′- TTCATTGTAT GGCTCCCTCT GTGGCCCTTG ACAT
GGGTGA TCCTCATGTC CTATAGTGAG TCGTATTA
#4615 5′- TTCATTGTAT GGCTCTCTCT GTGGCCCTTG ACA
TGGGTGA TCCTCATGTC CTATAGTGAG TCGTATTA
#4718 5′- TAGTGTCCAT TCATTGTATG GCTCCCTCTG TGGCC
CCTGG T
#4720 5′- TAGTGTCCAT TCATTGTATG GCTCTCTCTG TGGCC
CCTGG T
#4843 5′- CCGCTTCTTC CTTTCCAGAG G
#4849 5′- CCTCTGGAAA GAATTGGGT
vifmut-
forward
5′- AGGGCCACAG AGAGAGCCAT ACAATG
vifmut-reverse 5′- CATTGTATGG CTCTCTCTGT GGCCCT
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primer pair #2330/#3897. The respective PCR products
for pNL4-3 GI3-1 cmp (#4355/#4718) and pNL4-3 GI3-1
cmp/GI3-2 mut (#4355/#4720) containing PflMI and
XcmI restriction sites were cloned into pNL4-3 bysubstitution of the PflMI/XcmI fragment. Due to the
overlapping vif and vpr open reading frames (ORFs),
mutations resulted in single amino acid substitutions
(K181R GI3-1 cmp; G185E GI3-2 mut) within the Vif
protein (Figure 8D). pXGH5 [70] was co-transfected to
monitor transfection efficiency in quantitative and semi-
quantitative RT-PCR analyses. pcDNA3.1 Vif and pcDNA
Vif-V5 plasmids [71] were used to introduce point muta-
tion G185E by site directed mutagenesis using PCR
primers (vifmut-forward/vifmut-reverse). PCR products
were treated for 1 h at 37°C with 10 units of DpnI restric-
tion enzyme to digest the parental methylated plasmids
and transformed into E. coli. All PCR-amplified sequences
of the plasmids were validated by DNA-sequencing.
Oligonucleotides
All DNA oligonucleotides (Table 1) were obtained from
Metabion (Germany), those used for real time PCR ana-
lysis were HPLC purified. RNase-Free HPLC purified
LNAs (GI3-2: TATGGCTCCCTCTGTG; GI3-2 mismatch
control: TTTGGCTCACTCCGTG) were purchased from
Exiqon (Denmark).
Cell culture, transfection conditions and preparation of
virus stocks
HEK 293 T and HeLa cells were maintained in Dulbecco’s
high glucose modified Eagle’s medium (Invitrogen) sup-
plemented with 10% (v/v) heat-inactivated fetal calf serum
(FCS) and 50 μg/ml of penicillin and streptomycin (P/S)
each (Invitrogen). Transient transfection experiments
were performed in six-well plates (2.5 × 105 cells per well)
using TransIT®-LT1 transfection reagent (Mirus Bio LLC)
according to the manufacturer’s instructions. For LNA
co-transfection experiments, 2.5 × 105 HeLa cells per well
(six-well plate) were cultured in Opti-MEM reduced
serum medium (Invitrogen) with 5% FCS. The next day,
medium was replaced with Opti-MEM reduced serum
medium without FCS. For LNA transfection 4 μl of
Lipofectamine 2000 (Invitrogen) was added to 250 μl
Opti-MEM reduced serum medium. Separately, proviral
plasmid pNL4-3 (0.7 μg), plasmid pXGH5 (0.7 μg) and the
respective LNAs (80 nM) were added to 250 μl Opti-MEM
reduced serum medium. After 5 min the LNA/DNA mix-
tures were added to the Lipofectamine 2000 containing
medium, incubated for 20 min and subsequently added to
the cells. After 4 hours, medium was removed and cells
were washed twice with PBS and cultured with Opti-MEM
reduced serum medium with 5% FCS for 24 hours.
For preparation of virus stocks 6.5 x 106 HEK 293 T
cells were cultured in T175 flasks that were previously
coated with 0.1% gelatine solution. Cells were transiently
transfected with 9 μg of pNL4-3 or mutant proviral
DNA using polyethylenimine (Sigma-Aldrich). Following
overnight incubation, cells were supplemented with fresh
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P/S. 48 hours post transfection, virus containing super-
natant was purified by centrifugation, aliquoted and
stored at −80°C. Transfection efficiency was monitored
by using pNL4-3 GFP [72].
CEM-A and CEM-SS cells were maintained in RPMI
1640 medium (Invitrogen) supplemented with 10% FCS
and P/S (50 μg/ml each, Invitrogen). Peripheral blood
mononuclear cells (PBMCs) were isolated from 15 ml
whole blood from two healthy donors by ficoll gradient
centrifugation. PBMCs were maintained in RPMI 1640
GlutaMax medium containing 10% FCS and 1% P/S and
activated with phytohemagglutinin PHA (5 μg/ml). 48 hours
post isolation cells were treated with IL-2 (30 mg/ml).
RNA-isolation, quantitative and semi-quantitative RT-PCR
Total RNA was isolated by using acid guanidinium
thiocyanate-phenol-chloroform as described previously
[73]. RNA concentration and quality was analyzed by
photometric measurement using Nano-Drop 1000 spectro-
photometer, ND-1000 version 3.7.0 (Thermo Scientific).
Reverse transcription of 5 μg of total RNA was performed
as described previously [34]. For quantitative and qualita-
tive analysis of HIV-1 mRNAs the indicated primers
(Table 1) were used to amplify the cDNA-template. As a
loading control, a separate PCR detecting GAPDH was
performed with primers #3153 and #3154. PCR products
were separated on non-denaturing polyacrylamide gels
(10%), stained with ethidium bromide and visualized with
the Intas Gel iX Darkbox II (Intas, Germany). Quantitative
RT-PCR analysis was performed by using Precision 2×
real-time PCR MasterMix with SYBR green (Primerdesign,
UK) using LightCycler 1.5 (Roche). Primers used for quali-
tative and quantitative RT-PCR are listed in Table 1.
Protein isolation and Western blotting
For protein isolation cells were lysed using RIPA lysis
buffer (25 mM Tris HCl [pH 7.6], 150 mM NaCl, 1%
NP-40, 1% sodium deoxycholate, 0.1% SDS, protease
inhibitor cocktail [Roche]). Subsequently, the lysates were
subjected to SDS-PAGE under denaturating conditions
[74] in 8-12% polyacrylamide gels (Rotiphorese Gel 30,
Roth) as described before [34]. The following primary
antibodies were used for immunoblot analysis: Sheep anti-
body against HIV-1 p24 CA from Aalto (Ireland); mouse
monoclonal antibodies specific for HIV-1 Vif (ab66643)
and hnRNP F +H proteins (ab10689) from Abcam
(United Kingdom); hnRNPA2/B1 (DP3B3): sc-32316 from
Santa Cruz; rabbit anti-HIV-1-Vpr (51143-1-AP) polyclonal
antibody from Proteintech Group (United Kingdom); rabbit
polyclonal antibody against MS2 (TC-7004) from Tetracore
(Rockwill, USA); mouse anti β-actin monoclonal antibody
(A5316) from Sigma-Aldrich. The following horseradish
peroxidase (HRP) conjugated secondary antibodies wereused: anti-rabbit HRP conjugate (A6154) from Sigma-
Aldrich; anti-mouse antibody (NA931) from GE Healthcare
(Germany), and anti-sheep HRP from Jackson Immu-
noresearch Laboratories Inc. (West Grove, PA). Blots
were visualized by an ECL chemiluminescence detection
system (Amersham) and Intas ChemoCam imager (Intas,
Germany).
For analysis of expression of viral structural proteins,
Vif and A3G transfected cells were harvested, washed
with PBS and lysed using RIPA assay buffer for 20 min on
ice [25 mM Tris (pH 8.0), 137 mM NaCl, 1% glycerol,
0.1% SDS, 0.5% Na-deoxycholate, 1% Nonidet P-40, 2 mM
EDTA, and complete protease inhibitor mixture (Roche)].
Soluble lysates were clarified by centrifugation and sub-
jected to SDS-PAGE followed by transfer to a PVDF
membrane (Millipore). Viral particles were concentrated
by ultracentrifugation over 20% sucrose cushion (in PBS)
in ultra-clear centrifuge tubes (13 × 51 mm, Beckman
Coulter) and centrifuged at 37,000 rpm for 2 h at 4°C in
an MLS-50 rotor (Beckman Coulter). Pelleted particles
were lysed by RIPA assay buffer and directly subjected to
immunoblotting. Membranes were probed with mouse
anti-HA antibody to detect A3G (1:104 dilution; Covance,
Munich, Germany), mouse anti-Vif antibody (1:103) [75]
p24 was detected using mouse p24/p27 monoclonal
antibody AG3.0 (1:250) [76]. Mouse anti-VSV-G (1:2×
104 dilutions; Sigma-Aldrich), anti-mouse horseradish per-
oxidase (1:104 dilution; GE Healthcare, Munich, Germany).
Alpha-tubulin was detected using an anti-tubulin antibody
(1:104 dilution; Sigma-Aldrich). Signals were visualized by
ECL prime reagent (GE Healthcare).
Northern blotting
For Northern blotting of HIV-1 mRNAs 3 μg of total
RNA were separated on denaturing 1% agarose gel and
capillary blotted onto positively charged nylon mem-
brane and hybridized with an digoxigenin (DIG)-labeled
HIV-1 exon 7 PCR-amplicon (#3387/#3388) as previously
described [34].
Measurement of HIV-1 replication kinetics
Virus containing supernatants, which were generated by
transient transfection of HEK 293 T cells (see above),
were assayed for p24-CA via p24-CA ELISA or alterna-
tively for TCID50 as determined by calculation of X-Gal
stained TZM-bl cells. 4 × 105 CEM-SS or CEM-A cells
were infected with 1.6 ng of p24-CA of WT and mutant
viruses in serum-free RPMI medium at 37°C for 6 hrs.
Infected cells were washed in PBS (Invitrogen) and re-
suspended in RPMI media (Invitrogen) containing 10%
FCS and 1% P/S (Invitrogen). Aliquots of cell-free media
were harvested at intervals and subjected to p24-CA
ELISA (see below). 8 × 105 PBMCs were infected with
the indicated MOI as determined by TCID50 calculation.
Widera et al. Retrovirology 2014, 11:72 Page 16 of 19
http://www.retrovirology.com/content/11/1/72p24-CA ELISA
For HIV-1 p24-CA quantification using twin-site sandwich
ELISA [77,78] Nunc-Immuno 96 MicroWell solid plates
(Nunc) were coated with anti p24 polyclonal antibody
(7.5 μg/ml of D7320, Aalto) in bicarbonate coating buffer
(100 mM NaHCO3 pH 8.5) and incubated overnight
at room temperature. Subsequently, the plates were
washed with TBS (144 mM NaCl, 25 mM Tris pH 7.5).
HIV in the cell culture supernatant was inactivated by
adding Empigen zwitterionic detergent (Sigma, 45165)
followed by incubation at 56°C for 30 min. After p24
capturing and subsequent TBS-washing, sample specific
p24 was quantified by using an alkaline phosphatase-
conjugated anti-p24 monoclonal antibody raised against
conserved regions of p24 (BC 1071 AP, Aalto) using the
AMPAK detection system, (K6200, Oxoid (Ely) Ltd). For a
p24 calibration curve, recombinant p24 was treated as
described above.Infectivity assay
Transfections of HEK 293 T cells were performed using Li-
pofectamine LTX reagent (Invitrogen, Karlsruhe, Germany).
HIV-1 luc reporter vectors were produced in the presence
and absence of A3G, wild type (wt) Vif, wt Vif-V5, Vif
G185E and Vif-V5 G185E or empty vector (pcDNA3.1)
by transient transfection of 600 ng of pMDLg/pRRE,
250 ng of pRSV-Rev, 150 ng of pMD.G (VSV-G) and
600 ng of reporter vector pSIN.PPT.CMV.Luc.IRES-
GFP. The HIV-1 packaging plasmid pMDLg/pRRE
encodes gag-pol and the pRSV-Rev HIV-1 rev [79]. The
HIV-1 derived vector pSIN.PPT.CMV.Luc.IRES.GFP
expresses the firefly luciferase and GFP. The luciferase
cDNA (luc 3) was cloned into NheI and BamHI restric-
tion sites of pSIN.PPT.CMVmcsIRES.GFP [80], a gift of
Neeltje Kootsta. A3G and Vif expression plasmids were
kept in a ratio of 1:1 (600 ng each). 48 h post transfection,
viral particles containing supernatants were collected and
stored at −80°C until they were used. RT activity was
quantified using the Lenti-RT Activity Assay (Cavidi Tech,
Uppsala, Sweden).
To determine virus rescuing activity of wt Vif and Vif
G185E (and the V5 tagged version) HEK 293 T cells
were transduced in the presence or absence of A3G with
normalized amounts of viral like particles (determined
by RT activity). Two days after transduction, intracellular
luciferase activity was quantified using Steady Lite HTS
(Perkin-Elmer). Data were presented as the average of
actual luciferase activity per ten seconds of the quadru-
plicate (with mean and standard deviations). Statistically
significant differences between two groups were analyzed
using unpaired Student’s t test in GraphPad Prism, version
5 (GraphPad Software, San Diego, CA). A minimum P
value of 0.05 was considered statistically significant.HIV-sequence alignments and sequence logos
HIV-1 sequences were downloaded from the Los Alamos
HIV-1 Sequence Compendium 2012 (http://www.hiv.lanl.
gov/). The subtype sequences were analysed with the RIP
3.0 software (http://www.hiv.lanl.gov/content/sequence/
RIP/RIP.html). Sequence logos were generated by using
R Statistical Computing (http://www.r-project.org) and
R package seqLogo version 1.28.0 [81].RNA pull-down
Pre-annealed DNA oligonucleotides containing GI3-2 wt
and mutant sequences as well as a single copy of the MS2
binding site and T7 sequences (Table 1) were subjected to
in vitro transcription using RiboMAX™ Large Scale RNA
Production Systems (Promega) according to the manufac-
tures instructions (T7 Primer: #4324; GI3-2 wt: #4614;
GI3-2 mut: #4615). Following a phenol-chloroform extrac-
tion, the RNAs were covalently immobilized on adipic
acid dihydrazide-agarose beads (Sigma) and incubated
in 60% HeLa cell nuclear extract (Cilbiotech) in buffer
D (20 mM HEPES-KOH [pH 7.9], 5% [vol/vol] glycerol,
0.1 M KCl, 0.2 mM EDTA, 0.5 mM dithiothreitol). Recom-
binant MS2 protein (1 μg) was added to compare the input
of each sample. Unspecific bound proteins were removed
by repetitive washing with buffer D containing 4 mM mag-
nesium chloride. The associated proteins were eluted by
heating at 95°C for 10 min, separated via SDS-PAGE (16%)
and subjected to immunoblot analysis. For interference
with protein:RNA interaction, wt RNA substrate was pre-
incubated with the GI3-2 LNA in a ratio of either 1:5 or 1:1
relative to the amount of RNA substrate (1000 pmol).Additional file
Additional file 1: Figure S1. Binding sites of RT-PCR primers used in
this work. Schematic illustration of the positions of all NL4-3 related PCR
primers used in quantitative and qualitative RT-PCR assays. Locations of 5′
and 3′ splice sites (ss), exons and introns are indicated. Vif and Vpr exons are
highlighted in red and blue. The positions of relevant PCR forward and
reverse primers are indicated by black triangles. Primer pairs were used as
follows: unspliced 9 kb mRNAs (#3389/#3390), intronless 2 kb mRNAs (#3391/
#3392), exon 2 containing viral mRNAs (#3395/#4843), exon 3 containing viral
mRNAs (#3397/#3636), vif mRNA (#3395/#3396), vpr mRNA (#3397/#3398),
tat1 mRNA (#3631/#3632), tat2 mRNA (#3395/#4849), tat3 mRNA (#3397/
#3632), and all viral mRNAs containing exon 7 (#3387/#3388).Abbreviations
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